Cancer Medicine

Article	Citations
Sarcopenia and adverse health‐related outcomes: An umbrella review of meta‐analyses of observational studies	134
Depression and prostate cancer risk: A Mendelian randomization study	91
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker	89
Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer	77
Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy	74
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma	74
Changing trends in the disease burden of esophageal cancer in China from 1990 to 2017 and its predicted level in 25 years	74
Development and validation of an immune‐related prognostic signature in lung adenocarcinoma	74
Enhancement of tumor lethality of ROS in photodynamic therapy	72
Role of the oral microbiota in cancer evolution and progression	69
Global trends in the incidence and mortality of esophageal cancer from 1990 to 2017	67
Perspectives, fears and expectations of patients with gynaecological cancers during the COVID‐19 pandemic: A Pan‐European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe	65
Global, regional and national incidence, mortality and disability‐adjusted life‐years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019	63
Disparities in telemedicine during COVID‐19	63
Patient and clinician experience of a serious illness conversation guide in oncology: A descriptive analysis	60
Artificial intelligence in oncology: Path to implementation	60
Chinese and global burdens of gastric cancer from 1990 to 2019	57
Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis	54
Prehabilitation exercise therapy for cancer: A systematic review and meta‐analysis	53
Exosome‐mediated delivery of miR‐204‐5p inhibits tumor growth and chemoresistance	53
The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population‐based retrospective matched cohort analysis	51
Symptom clusters experienced by breast cancer patients at various treatment stages: A systematic review	51
Safety and efficacy of photobiomodulation therapy in oncology: A systematic review	51
Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy	49
Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi‐institutional study	49

Exosomal miRNAs as biomarkers for diagnostic and prognostic in lung cancer	49
Relationship of established risk factors with breast cancer subtypes	48
Comprehensive review of implications of COVID‐19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic	48
The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis	48
AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer	47
COVID‐19 and Oncology: Service transformation during pandemic	46
Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China	46
The prognostic utility of pre‐treatment neutrophil‐to‐lymphocyte‐ratio (NLR) in colorectal cancer: A systematic review and meta‐analysis	45
Exosomes released from M2 macrophages transfer miR‐221‐3p contributed to EOC progression through targeting CDKN1B	44
Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer	44
Exosomal lncRNA H19 promotes the progression of hepatocellular carcinoma treated with Propofol via miR‐520a‐3p/LIMK1 axis	43
The artificial intelligence‐assisted cytology diagnostic system in large‐scale cervical cancer screening: A population‐based cohort study of 0.7 million women	42
Construction of a lipid metabolism‐related and immune‐associated prognostic signature for hepatocellular carcinoma	41
Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial	41
Perspectives and controversies regarding the use of natural products for the treatment of lung cancer	41
The effect of anticancer treatment on cancer patients with COVID‐19: A systematic review and meta‐analysis	40
BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway	39
Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: A systematic analysis of the Global Burden of Disease Study 1990–2017	39
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer	38
Integrated bioinformatics analysis of expression and gene regulation network of COL12A1 in colorectal cancer	38
Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019	38
Esophageal cancer: trends in incidence and mortality in China from 2005 to 2015	37
Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy	37
Machine learning for the prediction of bone metastasis in patients with newly diagnosed thyroid cancer	37
Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab	37
Pattern and prognosis of distant metastases in nasopharyngeal carcinoma: A large‐population retrospective analysis	37
Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma	36
Exosomal microRNA‐4661‐5p–based serum panel as a potential diagnostic biomarker for early‐stage hepatocellular carcinoma	36
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors	35
Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients	35
Role of tumor microenvironment in cancer progression and therapeutic strategy	34
Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next‐generation sequencing technique	34
Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma	34
Examining the association among fear of COVID‐19, psychological distress, and delays in cancer care	34
TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma	33
Prevalence and severity of long‐term physical, emotional, and cognitive fatigue across 15 different cancer entities	33
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients	33
Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer	33
Insulin‐like growth factor‐1 and site‐specific cancers: A Mendelian randomization study	33
Exosomal lncRNA FAM225A accelerates esophageal squamous cell carcinoma progression and angiogenesis via sponging miR‐206 to upregulate NETO2 and FOXP1 expression	32
Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment	32
The roles of ferroptosis regulatory gene SLC7A11 in renal cell carcinoma: A multi‐omics study	31
Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma	31
TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment	31
miR‐140‐3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2	31
Helicobacter pylori‐related risk predictors of gastric cancer: The latest models, challenges, and future prospects	31
Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan	30
Exosome–transmitted microRNA‐133b inhibited bladder cancer proliferation by upregulating dual‐specificity protein phosphatase 1	30
Circular RNA hsa_circRNA_102209 promotes the growth and metastasis of colorectal cancer through miR‐761‐mediated Ras and Rab interactor 1 signaling	30
MRI‐based radiomics nomogram to predict synchronous liver metastasis in primary rectal cancer patients	30

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists	30
COVID‐19 pandemic and impact on cancer clinical trials: An academic medical center perspective	30
Galangin promotes cell apoptosis through suppression of H19 expression in hepatocellular carcinoma cells	29
LncRNA PITPNA‐AS1 boosts the proliferation and migration of lung squamous cell carcinoma cells by recruiting TAF15 to stabilize HMGB3 mRNA	29
Disparities in cancer‐related healthcare among people with intellectual disabilities: A population‐based cohort study with health insurance claims data	29
Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials	29
Development and validation of MRI‐based deep learning models for prediction of microsatellite instability in rectal cancer	29
The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study	29
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer	29
LncRNA MALAT1 accelerates non‐small cell lung cancer progression via regulating miR‐185‐5p/MDM4 axis	28
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomi	28
Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis	28
A systematic review and meta‐analysis of the prognostic role of age in oral tongue cancer	28
Risk factors and predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer	28
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use	28
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC	28
Cell‐free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience	28
COVID‐19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment	28
Immunotherapies for hepatocellular carcinoma	28
The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels	28
A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort	28
Geriatric assessment domains to predict overall survival in older cancer patients: An analysis of functional status, comorbidities, and nutritional status as prognostic factors	28
LncRNA NUTM2A‐AS1 positively modulates TET1 and HIF‐1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR‐376a	28
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer	27
MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer	27
Resveratrol suppresses the growth and metastatic potential of cervical cancer by inhibiting STAT3Tyr705 phosphorylation	27
The cancer patient’s perspective of COVID‐19‐induced distress—A cross‐sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic	27
LncRNA LINC00857 regulates the progression and glycolysis in ovarian cancer by modulating the Hippo signaling pathway	27
225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models	27
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial	27
Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy	27
A population study of screening history and diagnostic outcomes of women with invasive cervical cancer	27
Checkpoint inhibitor/interleukin‐based combination therapy of cancer	26
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis	26
Long noncoding RNA HCG18 up‐regulates the expression of WIPF1 and YAP/TAZ by inhibiting miR‐141‐3p in gastric cancer	26
Using deep learning to identify bladder cancers with FGFR‐activating mutations from histology images	26
Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis	26
HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3	26
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively	26
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer	26
Exosome‐transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma	26
Long‐term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy	26
Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION study	25
Stromal score as a prognostic factor in primary gastric cancer and close association with tumor immune microenvironment	25
Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression	25
The immune landscape during the tumorigenesis of cervical cancer	25
Long noncoding RNA MSC‐AS1 promotes hepatocellular carcinoma oncogenesis via inducing the expression of phosphoglycerate kinase 1	25
Prediction of lung metastases in thyroid cancer using machine learning based on SEER database	25
Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients	25
Circular RNA: A promising new star for the diagnosis and treatment of colorectal cancer	25
EBV‐positive B‐cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency	25
Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and pancreatic cancer incidence and mortality: A prospective cohort study	25
Circ‐UBAP2 functions as sponges of miR‐1205 and miR‐382 to promote glioma progression by modulating STC1 expression	25
Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium	24
Sex differences in solid pseudopapillary neoplasm of the pancreas: A population‐based study	24
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature	24
Marital status and survival in cancer patients: A systematic review and meta‐analysis	24
Retracted: Circ‐SPECC1 modulates TGFβ2 and autophagy under oxidative stress by sponging miR‐33a to promote hepatocellular carcinoma tumorigenesis	24
Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection	24
Association of image‐defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma	24
Seven immune‐related genes prognostic power and correlation with tumor‐infiltrating immune cells in hepatocellular carcinoma	24
A practical nomogram and risk stratification system predicting the cancer‐specific survival for patients with early hepatocellular carcinoma	24
Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial‐ethnic group, United States 2003‐2016	24
EO771, is it a well‐characterized cell line for mouse mammary cancer model? Limit and uncertainty	24
A novel five‐gene signature predicts overall survival of patients with hepatocellular carcinoma	24
Long noncoding RNA HCG11 inhibited growth and invasion in cervical cancer by sponging miR‐942‐5p and targeting GFI1	24
SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis	24
nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients	24
Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib	24
Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany	24
A modifiable risk factors atlas of lung cancer: A Mendelian randomization study	24
Long noncoding RNA MCM3AP‐AS1 enhances cell proliferation and metastasis in colorectal cancer by regulating miR‐193a‐5p/SENP1	24
Radiation therapy and secondary malignancy in Li‐Fraumeni syndrome: A hereditary cancer registry study	24
BRAF mutation and its inhibitors in sarcoma treatment	23
Lidocaine inhibits the metastatic potential of ovarian cancer by blocking NaV1.5‐mediated EMT and FAK/Paxillin signaling pathway	23
Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma	23
NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability	23
Serum N‐Glycome analysis reveals pancreatic cancer disease signatures	23
Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker	23
Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer	23

Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer	23
Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels	23
Impact of early palliative care according to baseline symptom severity: Secondary analysis of a cluster‐randomized controlled trial in patients with advanced cancer	23
The clinical application value of mixed‐reality‐assisted surgical navigation for laparoscopic nephrectomy	23
Artificial intelligence‐assisted colonoscopy: A prospective, multicenter, randomized controlled trial of polyp detection	22
Clinical implications of next‐generation sequencing‐based panel tests for malignant ovarian tumors	22
Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration	22
Metabolic dysfunction and early‐onset colorectal cancer – how macrophages build the bridge	22
N6‐methyladenine‐related genes affect biological behavior and the prognosis of glioma	22
Racial disparities negatively impact outcomes in early‐onset colorectal cancer independent of socioeconomic status	22
Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Dat	22
The bigger picture of shared decision making: A service design perspective using the care path of locally advanced pancreatic cancer as a case	22
Intratumor heterogeneity: A new perspective on colorectal cancer research	22
MiR‐362 suppresses cervical cancer progression via directly targeting BAP31 and activating TGFβ/Smad pathway	22
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma	22
Diagnostic significance and carcinogenic mechanism of pan‐cancer gene POU5F1 in liver hepatocellular carcinoma	22
Identification and validation of a ferroptosis‐related gene signature for predicting survival in skin cutaneous melanoma	22
The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues	22
Incidence and survival of rare cancers in the US and Europe	22
Correlation of tumor‐infiltrating immune cells of melanoma with overall survival by immunogenomic analysis	21
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma	21
Development and validation of a prognostic nomogram for predicting cancer‐specific survival after radical cystectomy in patients with bladder cancer:A population‐based study	21
WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma	21
Global, regional, and national burden of cancers attributable to tobacco smoking in 204 countries and territories, 1990–2019	21
Decreasing trends in thyroid cancer incidence in South Korea: What happened in South Korea?	21
Contemporaneous symptom networks of multidimensional symptom experiences in cancer survivors: A network analysis	21
Indocyanine green is a sensitive adjunct in the identification and surgical management of local and metastatic hepatoblastoma	21
Predictive role of diffusion‐weighted whole‐body MRI (DW‐MRI) imaging response according to MY‐RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined e	21
Age‐specific prevalence and determinants of depression in long‐term breast cancer survivors compared to female population controls	21
Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer	21
The lncRNA XIST/miR‐125b‐2‐3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer	21
Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer	21
Identification of novel subtypes based on ssGSEA in immune‐related prognostic signature for tongue squamous cell carcinoma	21
HHLA2 deficiency inhibits non‐small cell lung cancer progression and THP‐1 macrophage M2 polarization	21
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis	21
Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women	20
Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database	20
TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis	20
Uridine phosphorylase 1 is a novel immune‐related target and predicts worse survival in brain glioma	20
Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis	20
miRNA‐122‐5p in POI ovarian‐derived exosomes promotes granulosa cell apoptosis by regulating BCL9	20
Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis	20
Fat mass and obesity‐associated protein regulates tumorigenesis of arecoline‐promoted human oral carcinoma	20
A real‐world data of Immune checkpoint inhibitors in solid tumors from India	20
A measure of case complexity for streamlining workflow in multidisciplinary tumor boards: Mixed methods development and early validation of the MeDiC tool	20
Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches	20
Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer	20
Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti‐Lag‐3 via reducing FGL1 expression	20
The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial	20
Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer	20
A multicentre cross‐sectional observational study of cancer multidisciplinary teams: Analysis of team decision making	20
Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real‐world pharmacoepidemiology study of post‐marketing surveillance data	20
Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy	20
LncRNA TMPO‐AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR‐329‐3p to stimulate FOXK1‐mediated AKT/mTOR signaling pathway	20
Gut microbiota and risk of five common cancers: A univariable and multivariable Mendelian randomization study	20
Joint effect of tobacco, alcohol, and oral HPV infection on head and neck cancer risk in the French West Indies	20
Comprehensive molecular profiling broadens treatment options for breast cancer patients	20
Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review	19
Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors	19
Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma	19
Health care‐related time costs in patients with metastatic breast cancer	19
Systematic review of neighborhood socioeconomic indices studied across the cancer control continuum	19
Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study	19
Long noncoding RNA FOXD2‐AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR‐206/MAP3K1 axis	19
Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer	19
Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high‐level immune infiltration status	19
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer	19
Body mass index associated with childhood and adolescent high‐risk B‐cell acute lymphoblastic leukemia risk: A Children’s Oncology Group report	19
Breastfeeding reduces the risk of breast cancer: A call for action in high‐income countries with low rates of breastfeeding	19
Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios	19
Discovery and validation of novel biomarkers for detection of cervical cancer	19
Association between pre‐diagnostic serum albumin and cancer risk: Results from a prospective population‐based study	19
A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer	19
Body mass index trajectories and prostate cancer risk: Results from the EPICAP study	19
miR‐18a activates Wnt pathway in ER‐positive breast cancer and is associated with poor prognosis	19
Patient‐derived scaffolds as a model of colorectal cancer	19
Characteristics and prognosis of synchronous multiple primary lung cancer after surgical treatment: A systematic review and meta‐analysis of current evidence	19
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies	19
Exercise intervention decreases acute and late doxorubicin‐induced cardiotoxicity	18
The patient perspective in the era of personalized medicine: What about scanxiety?	18
MASTL: A novel therapeutic target for Cancer Malignancy	18
A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma	18
Downregulation of KIAA1199 by miR‐486‐5p suppresses tumorigenesis in lung cancer	18
Ultra‐mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns	18
Delayed initiation of adjuvant chemotherapy in older women with breast cancer	18
Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease	18
Retracted: SLCO4A1‐AS1 promotes cell growth and induces resistance in lung adenocarcinoma by modulating miR‐4701‐5p/NFE2L1 axis to activate WNT pathway	18
Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses	18
Plasma metabolomic profile associated with fatigue in cancer patients	18
Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes	18
Sarcopenia on preoperative chest computed tomography predicts cancer‐specific and all‐cause mortality following pneumonectomy for lung cancer: A multicenter analysis	18
Trametinib therapy for children with neurofibromatosis type 1 and life‐threatening plexiform neurofibroma or treatment‐refractory low‐grade glioma	18
ALOX5‐5‐HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation	18
Comparison of quality of life and cosmetic result between open and transaxillary endoscopic thyroid lobectomy for papillary thyroid microcarcinoma survivors: A single‐center prospective cohort study	18
Periplocin inhibits the growth of pancreatic cancer by inducing apoptosis via AMPK‐mTOR signaling	18